The treatment of glaucoma remains a challenge due to the specific structure of the eye. Effective treatment by optimizing drug delivery is currently an important direction of current glaucoma research.
Dendrimers are a promising class of innovative polymeric nanocarriers for targeted delivery systems to treat glaucoma. They are branched synthetic polymers with multiple surface groups, unique structures and high-water solubility. Due to their structure, dendrimers can interact with drug molecules to form physical complexes or chemical adducts, thereby increasing bioavailability, cellular uptake and therapeutic efficacy.
Ace Therapeutics is committed to developing innovative, effective and less burdensome dendrimer delivery systems. We offer a range of research services for the preparation, characterization and evaluation of dendrimers. Our goal is to investigate and develop novel glaucoma drug delivery systems for our clients to improve the efficacy of drug delivery.
Dendrimer
Dendrimers are made of polymeric materials with extensive and flexible branching. Their high strength branching can be used to trap drugs for drug delivery. Dendrimers are usually spherical or ellipsoidal in shape. They consist of three components, which are a central core, branching and functional groups present on the surface.
Fig. 1 The structural diversity, adaptability and flexible loading capacity of dendrimers. (Yadav K S, et al., 2019)
Dendrimers encapsulate or couple the drug by interaction with the drug. Their interaction may be through physical trapping or chemical interactions. The drug can be covalently bound to the surface of the dendrimer through esters, amides or other chemical bonds. These hydrolysable or biodegradable junctions can provide precise control of drug release.
Services for Dendrimer Delivery System Development for Glaucoma
Dendrimers have been widely used as drug delivery vehicles in various forms. For glaucoma, we provide solutions for dendrimer-based drug delivery systems. We research and develop new dendritic structures, prepare dendrimer formulations, characterize new drugs, and enable the development of new and efficient glaucoma therapies.
- Synthesis procedure of dendrimer
We develop and use different synthesis methods based on different dendritic polymers. New synthetic methods can be used to reduce the number of synthesis steps and the consumption of chemicals, thus reducing the cost of the final product. Our available methods include, but are not limited to, divergent method, hypermonomer method and branched monomer approach, Lego chemistry, click chemistry, double exponential, etc. - Characterization and evaluation procedure for dendrimer formulations
Following the synthesis of the adduct formulation, we provide a series of characterization and evaluation analyses of the formulation. These include: determining the number of drug molecules attached to dendrimers, measuring particle size and zeta potential, and studying drug release behavior. We also offer in vitro cytotoxicity studies and in vivo studies, following guidelines for animal protocols.
Our Innovative Strengths
Dendrimers have many benefits as glaucoma drug delivery vehicles. We solve your development process challenges and make new progress for your project. We provide innovative strategies mainly in the areas of size limitation, surface modification, and drug release.
- Size-adaptive dendrimer strategy
- Charge reversal dendrimer strategy
- Dendrimer hydrogel strategy
- Micro/nanoscale dendrimer strategy
We hope that the drug-carrying dendrimer could be a promising alternative to glaucoma drugs. Dendrimers serve as a powerful ocular drug delivery vehicle, so if you need further research and development, please do not hesitate to contact us.
References
- Wang J, et al. Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng, 2022,16(18).
- Burçin Yavuz, et al. PAMAM dendrimer conjugates for retinal delivery: preparation, characterization and in vivo evaluation. Journal of Pharmacy and Pharmacology, 2016, 68(8):1010–1020.